Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
Mayo Clinic
University of Southern California
University of Pittsburgh
M.D. Anderson Cancer Center
UroGen Pharma Ltd.
Melanoma Institute Australia
German Cancer Research Center
AIDS Malignancy Consortium
National Cancer Institute (NCI)
LEO Pharma
Stemline Therapeutics, Inc.
Medical University of South Carolina
Baylor College of Medicine
AIDS Malignancy Consortium
University of Miami
Melanoma and Skin Cancer Trials Limited
Beth Israel Deaconess Medical Center
Yale University
Northwestern University
OX2 Therapeutics
University Children's Hospital Tuebingen
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Inovio Pharmaceuticals
Wake Forest University Health Sciences
Zealand University Hospital
University Hospital Tuebingen
Ludwig Institute for Cancer Research
University of Miami
Viatris Inc.
Viatris Inc.
Viatris Inc.
Viatris Inc.
Viatris Inc.
Viatris Inc.
Viatris Inc.
Viatris Inc.
Medical University of Graz
NYU Langone Health
Washington University School of Medicine
University Medical Centre Maribor
Medical University of Graz
Barretos Cancer Hospital
Icahn School of Medicine at Mount Sinai
Novartis
Teva Pharmaceuticals USA
Medical University Innsbruck
Actavis Inc.
Xiangya Hospital of Central South University
Kiromic BioPharma Inc.
University of Virginia